All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase

June 14th 2024

The FDA has approved blinatumomab (Blincyto) for use in select patients with CD19+ Ph– B-cell precursor acute lymphoblastic leukemia in the consolidation phase.

FDA Approves Durvalumab Plus Chemotherapy for dMMR Primary Advanced or Recurrent Endometrial Cancer

June 14th 2024

The FDA had approved durvalumab plus, followed by single-agent durvalumab, for dMMR primary advanced or recurrent endometrial cancer.

Earlier Use of Acalabrutinib Associated With Improved Survival in CLL

June 14th 2024

Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.

CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL

June 14th 2024

The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.

Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma

June 14th 2024

Englumafusp alfa plus glofitamab showed activity and tolerability in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis

June 14th 2024

Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.

CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL

June 14th 2024

The CD7-targeted CAR T-cell therapy WU-CART-007 had a manageable safety profile and elicited preliminary efficacy signals in relapsed/refractory T-ALL/LBL.

Disease Duration, Elevated WBC Count, and VAF Predict Disease Progression in Polycythemia Vera

June 14th 2024

Time from diagnosis, elevated WBC count, and VAF were all significantly associated with an increased risk of disease progression of polycythemia vera.

Observational Study Finds Progression Common in Lower-Risk Myelofibrosis

June 14th 2024

Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.

Liso-Cel Associated With Improved Benefit in Earlier Lines of Therapy in R/R Mantle Cell Lymphoma

June 14th 2024

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Zanubrutinib Plus Venetoclax Generates 100% ORR in Treatment-Naive Del17p/TP53+ CLL/SLL

June 14th 2024

Zanubrutinib/venetoclax elicited a 100% overall response rate in untreated chronic lymphocytic leukemia harboring 17p deletions or TP53 mutations.

Ide-Cel Generates Favorable PFS Outcomes in R/R Multiple Myeloma With Lower Tumor Burden

June 14th 2024

Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower tumor burden.

CAR T-Cell Therapy vs Bispecific Antibodies: Picking an Approach in R/R DLBCL

June 13th 2024

Marie Hu, MD, discusses considerations for the use of CAR T-cell therapy and bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma.

Luspatercept Generates Across-the-Board Benefit for Lower-Risk MDS in COMMANDS

June 13th 2024

Luspatercept elicited superior erythroid response rates and duration of RBC transfusion independence compared with epoetin alfa in lower-risk MDS.

Quadruplet Therapy and Early-Line CAR T-Cell Therapy Approvals Mark Shifting Standards in Multiple Myeloma

June 13th 2024

Minoo Battiwalla, MD, MS, discusses the impact of earlier-line FDA approvals for CAR T-cell therapies on treatment outcomes in multiple myeloma.

DESTINY-Breast06 Data Reveal Another Potential Avenue for T-DXd in HR+, HER2-Low Metastatic Breast Cancer

June 13th 2024

VK Gadi, MD, PhD, discusses findings from the DESTINY-Breast06 trial and the implications for hormone receptor–positive, HER2-low metastatic breast cancer.

FDA Grants Accelerated Approval to Repotrectinib for NTRK+ Solid Tumors

June 13th 2024

The FDA granted accelerated approval to repotrectinib (Augtyro) for select patients with solid tumors harboring a NTRK gene fusion.

IBI343 Receives FDA Fast Track Designation for Advanced/Metastatic PDAC

June 13th 2024

The FDA granted fast track designation to IBI343 monotherapy for relapsed/refractory advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Extends PFS in First-Line CLL

June 13th 2024

Venetoclax plus obinutuzumab with or without ibrutinib significantly improved PFS vs chemoimmunotherapy and vs venetoclax plus rituximab in frontline CLL.

A Surgeon’s Perspective: How to Optimize Outcomes With Neoadjuvant Chemo/IO in Lung Cancer

June 13th 2024

Eric Vallieres, MD, FRCSC, discusses the evolving role of surgery in lung cancer treatment following the implementation of new neoadjuvant and adjuvant treatments.